Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
2019 · The Lancet Oncology · 549 citations
https://doi.org/10.1016/s1470-2045(19)30328-6
S
Simon Lord
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
198
Papers
4.0K
Citations
27
h-index
44
i10-index
Simon Lord is an academic researcher from University of Oxford. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Glioma Diagnosis and Treatment & Radiopharmaceutical Chemistry and Applications. The author has an h-index of 27, co-authored 169 publications.
ORCID: 0000-0001-7946-5609Papers by this author
worksThe current status of risk-stratified breast screening
2021 · British Journal of Cancer · 123 citations
https://doi.org/10.1038/s41416-021-01550-3
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer
2018 · Cell Metabolism · 122 citations
https://doi.org/10.1016/j.cmet.2018.08.021
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?
2023 · British Journal of Cancer · 121 citations
https://doi.org/10.1038/s41416-023-02204-2
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
2021 · British Journal of Cancer · 98 citations
https://doi.org/10.1038/s41416-021-01406-w
Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases
2023 · Genome Medicine · 66 citations
https://doi.org/10.1186/s13073-023-01240-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat